Limitations, agreements, and source contact

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma · Source last updated 2026-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

CL_OPCJ_RDA_Team@otsuka.jp

organization

Otsuka Pharmaceutical Co., Ltd.

phone

+81-3-6361-7366

title

Director of Clinical Trials

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice